What we do Saroja Pharma Industries is a pharmaceutical trading company specializing in APIs, pharma intermediates, specialty chemicals and solvents for human and veterinary medications. |
Founded in 2,019 |
Market share Emerging player with growing market presence in India and Asia Pacific pharmaceutical trading sectors. |
Problem solved Provides cost-effective, high-quality raw materials enabling pharmaceutical manufacturers to meet stringent drug synthesis and antimicrobial resistance requirements. |
Top clients or who we serve B2B model serving leading pharmaceutical companies in India and international markets, including emerging Asia Pacific regions. |
Key management Biju Gopinathan Nair (Chairman & Managing Director), Manish Dasharath Kamble (Whole-Time Director) |
Our journey and innovations Founded in 2019, transitioned from private to public limited in 2023, launched IPO raising Rs. 9.11 crores, expanded to high-value pharma intermediates. |
Where we operate Primarily India with expanding footprint in Asia Pacific markets. |
Top products or what we offer Active Pharmaceutical Ingredients, Pharma Intermediates, Specialty Chemicals, Solvents for pharma production in human and veterinary medicines. |
Top brands - |
Raw materials needed Chemical raw materials for APIs, intermediates, and solvents used in pharma drug manufacturing. |
Raw materials supplier Sourced from various chemical manufacturers domestically and internationally (specific suppliers not disclosed). |
Recurring vs cyclical contribution Revenue primarily recurring from long-term trade contracts with pharma companies. |
Our industry position Growing presence with expanding revenues; recent IPO supports enhanced market reach and capacity. |
Financial highlights FY 2024-25 Revenue: Rs. 53.73 crore; Net Profit: Rs. 1.03 crore; Up from Rs. 40.67 crore revenue and Rs. 0.88 crore profit FY prior. |
Geographical revenue split India contributes approx. Rs. 49.17 crore; Asia Pacific approx. Rs. 4.56 crore revenue. |
Order book - |
Whats driving growth Rising demand for high-value pharma intermediates and stronger supply chains amid regulatory tightening on antimicrobials. |
Our future plans Expand manufacturing capacity and supply chain to serve emerging markets with specialty and high-value intermediates. |
Our green promise - |
Our people and values 12 employees; emphasizes governance, compliance, diversity, and ethical business practices. |
Key challenges ahead Managing regulatory changes, ensuring supply chain integrity, and competition in pharmaceutical chemicals trading. |
Interesting facts Rapid progression from private to public company within four years, successful IPO in 2023. |
Risks and strategy Mitigating market and regulatory risks through strong compliance, auditing, and diversification of product portfolio. |
